Associations of age, frailty status, and comorbidity status with post-operative outcomes following CRS-HIPEC.
Abstract
e16060 Background: Cytoreductive surgery, combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), is a promising intervention used to treat disseminated peritoneal cancers. However, not all patients with peritoneal disease are candidates for CRS-HIPEC. This study sought to assess how factors such as age, frailty, and comorbidity status are associated with postoperative outcomes for patients undergoing CRS-HIPEC, including complications, length of hospital stay, discharge disposition, and readmissions. Methods: A retrospective review of demographics, comorbidities, and post-operative data was performed on 216 patients who underwent CRS-HIPEC from 2018 through 2022 at a high-volume CRS-HIPEC academic institution. All patients independent of diagnoses were included, and patients under 18 years of age were excluded. Patients with a Modified Five-Item Frailty Index (mfi-5) score of ≥2 were considered clinically frail and those with Charlson Comorbidity Index (CCI) score of ≥3 were grouped as moderate-to-severe comorbidity status. Categorical associations were tested with Chi-square or Fisher’s exact tests. All tests were two-tailed and conducted in Statistical Analysis System® (SAS) software, Version 9.4. Results: 216 patients met the study’s inclusion criteria. Frailty was significantly associated with severe complications (OR 3.21, p = 0.01), non-routine discharges (OR 2.87, p = 0.046), and 90-day readmissions (OR 3.52, p = 0.003). Patients with higher CCI scores also demonstrated higher risks of severe complications (p = 0.03), non-routine discharges (p = 0.0015), and readmissions (p = 0.006). Elderly patients were more likely to require non-routine discharges (OR 0.23, p = 0.003) and had higher readmission rates (OR 0.33, p = 0.01) but were not at increased risk of severe complications. Conclusions: This study highlights frailty and comorbidity burden (CCI) as key predictors of adverse outcomes following CRS-HIPEC, with frailty strongly associated with severe complications, non-routine discharges, and readmissions. While elderly patients had higher rates of non-routine discharges and readmissions, age alone was a weaker predictor of complications compared to frailty and CCI. These findings suggest that age alone may not be a contraindication for CRS-HIPEC. Preoperative assessments focusing on frailty and comorbidities may better guide patient selection and postoperative care strategies to optimize outcomes.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (5)
Kaylee Gleason
University of Kansas School of Medicine - Wichita, Wichita, KS
Mazin Mazin Al-Kasspooles
University of Kansas Medical Center, Kansas City, KS
Hayrettin Okut
Jill Haley
University of Kansas School of Medicine, Kansas City, KS
Brian Dean
University of Kansas School of Medicine Wichita, Wichita, KS